Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1994 1
1995 3
1996 1
1997 3
1998 3
1999 7
2000 9
2001 3
2002 8
2003 9
2004 9
2005 10
2006 12
2007 7
2008 10
2009 3
2010 10
2011 8
2012 10
2013 9
2014 5
2015 5
2016 1
2017 7
2018 4
2019 4
2020 3
2021 6
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15550588

160 results

Results by year

Filters applied: . Clear all
Page 1
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C; European Organization for Research and Treatment of Cancer New Drug Development Group. Schöffski P, et al. Ann Oncol. 2004 Dec;15(12):1816-24. doi: 10.1093/annonc/mdh469. Ann Oncol. 2004. PMID: 15550588 Free article. Clinical Trial.
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).
Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H; European Organisation for Research and Treatment of Cancer. Bergmann L, et al. Eur J Cancer. 2008 Aug;44(12):1657-62. doi: 10.1016/j.ejca.2008.05.005. Epub 2008 Jul 2. Eur J Cancer. 2008. PMID: 18602257 Clinical Trial.
Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M. Schöffski P, et al. Ann Oncol. 2004 Apr;15(4):671-9. doi: 10.1093/annonc/mdh141. Ann Oncol. 2004. PMID: 15033678 Free article. Clinical Trial.
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL. Heery CR, et al. Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31. Lancet Oncol. 2017. PMID: 28373007 Free PMC article. Clinical Trial.
160 results